In this retrospective cohort study, oral
glucose tolerance testing (OGTT) was performed for all enrolled survivors of patients who suffered from
acute lymphoblastic leukemia (ALL) at least 9 months after ending
chemotherapy, as well as for control group. All demographic, treatment and anthropomorphic data were obtained from medical records. Furthermore,
insulin resistance was evaluated according to
insulin level, Matsuda and HOMA-IR index. Of 53 subjects, 28 exhibited B-cell ALL, and 25 were healthy children (F/M = 1.12/1). Mean age (±SD) was determined to be 10.77 ± 2.83 years, and meantime off for
therapy was also recorded as 3.0 ± 1.6 years. ALL patients were diagnosed at age 1-15 years; none of them received the cranial
radiotherapy, and demographic characteristics (age, sex, and sexual maturity) were found to be the same in both groups. Seven patients showed transient
hyperglycemia during ALL treatment, however, no significant differences were found in terms of body mass index (BMI) means between ALL patients with and without transient
hyperglycemia. Based on the data presented herein,
insulin resistance could not be predicted by
glucose levels during
therapy, cumulative
asparaginase, and
steroid. Our findings demonstrated that elevated BMI could be a valuable predictor of
insulin resistance probability in ALL patients. The presence of transient
hyperglycemia does not appear to be associated with the increased risk of
glucose intolerance or
insulin resistance in the first few years after completion of
therapy.